Medical treatment for gastro-entero-pancreatic neuroendocrine tumours

Table 1 Ongoing phaseIII trials in gastro-entero-pancreatic neuroendocrine tumours

ClinicalTrials.gov Identifier	Investigated drug	Target	Type of enrolled pts
NCT00171873	Octreotide LAR 30 mg	SSTR	Locally inoperable or metastatic well differentiated NETs of the midgut Naïve pts
NCT01524783	Everolimus plus BSC vs PBO plus BSC	mTOR	Unresectable or metastatic G1 or G2 neuroendocrine tumours of GI or lung Treatment-naïve pts and pre-treated pts (all available treatment options are allowed) with PD
NCT00842348	Lanreotide autogel 120 mg	SSTR	Non-functioning GEP-NETs
NCT00690430	Pasireotide LAR 60 mg vs Octreotide LAR 40 mg	SSTR	Metastatic carcinoid tumours Pts with disease-related symptoms inadequately controlled by somatostatin analogues
NCT00774930	Somatuline depot (lanreotide) vs PCB	SSTR	Carcinoid tumours with liver metastasis Treatment-naïve pts and pts pre-treated with and responsive to somatostatine analogues
NCT00092287	Lanreotide autogel vs Sandostatin LAR	SSTR	Carcinoid tumours localized in lung, stomach or midgut Treatment-naïve pts and pts pre-treated with and responsive to somatostatine analogues
NCT00263659	Telotristat etiprate (LX1606) vs PBO	TPH	Well-differentiated metastatic NETs with carcinoid syndrome Treatment-naïve pts
NCT01677910	Telotristat etiprate (LX1606) vs PBO	TPH	Well-differentiated metastatic NETs with carcinoid syndrome Pts with disease-related symptoms inadequately controlled by somatostatin analogues

GEP-NETs: Gastro-entero-pancreatic neuroendocrine tumours; LAR: Long acting release; SSTR: Somatostatin receptor; mTOR: Mammalian target of rapamycin; BSC: Best supportive care; PBO: Placebo; PD: Programmed death; TPH: Tryptophan hydroxylase; pts: Patients.